SHUBHAM PANT to Pyridines
This is a "connection" page, showing publications SHUBHAM PANT has written about Pyridines.
Connection Strength
0.674
-
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Invest New Drugs. 2022 10; 40(5):990-1000.
Score: 0.516
-
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clin Cancer Res. 2018 07 15; 24(14):3253-3262.
Score: 0.096
-
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res. 2022 Jun 02; 41(1):189.
Score: 0.032
-
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Invest New Drugs. 2021 08; 39(4):1089-1098.
Score: 0.029